Please try another search
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson’s disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson’s disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama.
Name | Age | Since | Title |
---|---|---|---|
J. Milton Harris | 83 | 2024 | Director |
Steven Michael Mintz | 58 | 2024 | Director |
Gaurav Sahay | - | - | Member of Scientific Advisory Board |
Charles Warren Olanow | - | - | Member of Scientific Advisory Board |
Gregory H. Bailey | 68 | 2024 | Director |
William K. Schmidt | 73 | - | Member of Scientific Advisory Board |
Richard Marshall | 57 | 2024 | Director |
Remy Gross | 54 | 2024 | Director |
Balkrishan Gill | 59 | 2024 | Executive Chairman |
Steven A. Ledger | 65 | 2024 | Interim CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review